[go: up one dir, main page]

MX2019010533A - Composicion para la medicion, prevencion o alivio del envejecimiento de la piel, usando hapln1. - Google Patents

Composicion para la medicion, prevencion o alivio del envejecimiento de la piel, usando hapln1.

Info

Publication number
MX2019010533A
MX2019010533A MX2019010533A MX2019010533A MX2019010533A MX 2019010533 A MX2019010533 A MX 2019010533A MX 2019010533 A MX2019010533 A MX 2019010533A MX 2019010533 A MX2019010533 A MX 2019010533A MX 2019010533 A MX2019010533 A MX 2019010533A
Authority
MX
Mexico
Prior art keywords
skin aging
hapln1
alleviating
composition
hapln1 protein
Prior art date
Application number
MX2019010533A
Other languages
English (en)
Inventor
Kyong Kim Dae
Fu Zhicheng
Jung Back Moon
Original Assignee
Haplnscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haplnscience Inc filed Critical Haplnscience Inc
Publication of MX2019010533A publication Critical patent/MX2019010533A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/148—Screening for cosmetic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Birds (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)

Abstract

La presente divulgación se refiere a proteína HAPLN1 de un individuo envejecido. La proteína HAPLN1 presenta expresión reducida con el envejecimiento, y cuando se administra, es excelente su efecto en aliviar y revertir el envejecimiento de la piel incluyendo arrugas. Por tanto, explotando la diferencia en la expresión, se proporcionan una composición de biomarcador para medir el envejecimiento de la piel, capaz de diagnosticar el envejecimiento de la piel; un kit; y un método de búsqueda de agentes de alivio del envejecimiento de la piel, que comprende detectar el nivel de expresión de proteína HAPLN1 o gen HAPLN1. Además, se proporcionan una composición farmacéutica, composición cosmética, o nutracéutico, para prevenir o aliviar el envejecimiento de la piel, y una composición cosmética o nutracéutico para aliviar arrugas, conteniendo cada uno una cualquiera o más seleccionados del grupo que consiste en proteína HAPLN1, un gen que codifica la misma, y un agente eficaz para promover la expresión o activación de las funciones de proteína o gen HAPLN1.
MX2019010533A 2017-03-06 2017-03-06 Composicion para la medicion, prevencion o alivio del envejecimiento de la piel, usando hapln1. MX2019010533A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2017/002395 WO2018164290A1 (ko) 2017-03-06 2017-03-06 Hapln1을 이용한 피부 노화 측정 또는 예방 또는 개선용 조성물

Publications (1)

Publication Number Publication Date
MX2019010533A true MX2019010533A (es) 2019-12-19

Family

ID=63448272

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010533A MX2019010533A (es) 2017-03-06 2017-03-06 Composicion para la medicion, prevencion o alivio del envejecimiento de la piel, usando hapln1.

Country Status (16)

Country Link
US (1) US11202749B2 (es)
EP (1) EP3594685B1 (es)
JP (1) JP2020514739A (es)
CN (1) CN110603448A (es)
AU (1) AU2017403257B2 (es)
BR (1) BR112019018469A2 (es)
CA (1) CA3055168C (es)
CO (1) CO2019009796A2 (es)
IL (1) IL269126B (es)
MX (1) MX2019010533A (es)
NZ (1) NZ756946A (es)
PE (1) PE20191707A1 (es)
RU (1) RU2750486C2 (es)
SG (1) SG11201908160VA (es)
WO (1) WO2018164290A1 (es)
ZA (1) ZA201905864B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113490500A (zh) * 2019-02-28 2021-10-08 哈普赛安思有限公司 包括hapln1的用于预防、改善或治疗与软骨有关的疾病或症状的组合物
KR102166453B1 (ko) * 2020-02-03 2020-10-15 중앙대학교 산학협력단 Hapln1을 포함하는 폐질환 예방 또는 치료용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6156114A (ja) * 1984-08-27 1986-03-20 Kanebo Ltd 皮膚老化防止用化粧料
DE10100121A1 (de) * 2001-01-03 2002-08-01 Henkel Kgaa Verfahren zur Bestimmung des Hautstreß oder der Hautalterung in vitro
GB0422525D0 (en) 2004-10-11 2004-11-10 Luebcke Peter Dermatological compositions and methods
US20090220488A1 (en) * 2005-08-31 2009-09-03 Humphrey Gardner Evaluating and treating scleroderma
US7908090B2 (en) * 2005-11-30 2011-03-15 The Board Of Trustees Of The Leland Stanford Junior University Signatures for human aging
WO2008013934A2 (en) * 2006-07-27 2008-01-31 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
SI2132562T1 (sl) * 2007-04-06 2012-05-31 Genzyme Corp Metode za ovrednotenje celic in celičnih kultur
KR100921971B1 (ko) * 2007-10-24 2009-10-15 한국과학기술연구원 블루밍샐리 추출물을 유효성분으로 함유하는 조성물
EP2704728A4 (en) * 2011-05-03 2015-04-22 Dermachip Inc EXPRESSION SIGNATURES OF AGENTS ASSOCIATED WITH SKIN AGING AND GEN NETWORKS
EP2710373B1 (en) * 2011-05-17 2015-06-17 Chanel Parfums Beauté Screening of large activators for preventing and/or attenuating skin ageing and/or hydrating skin
DE102011085497A1 (de) * 2011-10-31 2013-05-02 Evonik Industries Ag Kosmetische Formulierung
WO2013129456A1 (ja) * 2012-02-29 2013-09-06 ロート製薬株式会社 線維芽細胞増殖促進能を有する組成物
JP6185549B2 (ja) * 2012-03-16 2017-08-23 ソウル大学校産学協力団Ｓｎｕ Ｒ＆Ｄｂ Ｆｏｕｎｄａｔｉｏｎ 新規のｔｒｐｖ１抑制ペプチド及びこれを含有する皮膚老化防止またはしわ改善用組成物
JP6094481B2 (ja) * 2012-05-02 2017-03-15 三菱レイヨン株式会社 皮膚に対する紫外線の影響を評価するためのプローブ又はプローブセット及び核酸マイクロアレイ
WO2015017625A1 (en) * 2013-07-31 2015-02-05 Wikifoods, Inc. Encapsulated functional food compositions
GB201505520D0 (en) * 2015-03-31 2015-05-13 Univ Lancaster Composition
KR101897340B1 (ko) * 2015-09-09 2018-09-13 중앙대학교 산학협력단 Hapln1을 이용한 피부 노화 측정 또는 예방 또는 개선용 조성물

Also Published As

Publication number Publication date
CO2019009796A2 (es) 2019-09-18
US11202749B2 (en) 2021-12-21
EP3594685B1 (en) 2024-11-06
JP2020514739A (ja) 2020-05-21
US20200000700A1 (en) 2020-01-02
CA3055168A1 (en) 2018-09-13
WO2018164290A1 (ko) 2018-09-13
IL269126B (en) 2021-01-31
EP3594685A4 (en) 2020-11-18
PE20191707A1 (es) 2019-11-28
AU2017403257A1 (en) 2019-09-26
NZ756946A (en) 2022-07-01
ZA201905864B (en) 2021-10-27
AU2017403257B2 (en) 2021-09-30
RU2750486C2 (ru) 2021-06-28
RU2019131360A3 (es) 2021-04-07
CA3055168C (en) 2022-09-06
RU2019131360A (ru) 2021-04-07
BR112019018469A2 (pt) 2020-04-14
EP3594685A1 (en) 2020-01-15
CN110603448A (zh) 2019-12-20
SG11201908160VA (en) 2019-10-30

Similar Documents

Publication Publication Date Title
GEP20237528B (en) Antibodies against signal-regulatory protein alpha and methods of use
WO2012116081A3 (en) Methods for identifying cosmetic agents for skin care compositions
BR112015022934A8 (pt) esteróides neuroativos, composições e usos destes
EP4335931A3 (en) Therapeutic and diagnostic methods for cancer
BR112018069876A2 (pt) composição cosmética, método para fotoestabilização de resveratrol, polidatina, ou uma mistura dos mesmos com baicalina e método
WO2009090553A3 (en) Compositions and methods of detecting post-stop peptides
HK1213830A1 (zh) 用於预测醋酸格拉替雷临床反应的生物标志物
MY192532A (en) Liquid pharmaceutical composition
WO2014169226A3 (en) Methods of diagnosing and treating chronic pain
SG10201808208PA (en) Agent comprising imidazole dipeptide
SG10201901713RA (en) Extracellular matrix compositions
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
WO2016161415A3 (en) Tnfrsf14/ hvem proteins and methods of use thereof
MX2017005126A (es) Metodos y composiciones para el diagnostico y pronostico de lesion renal e insuficiencia renal.
MX2021014898A (es) Mejoramientos en o relacionados con compuestos organicos.
CL2018001343A1 (es) Lactoferrina para uso en el diagnóstico o el pronóstico de la enfermedad de alzheimer o en el diagnóstico de la enfermedad de parkinson
EP3285071A4 (en) Biomarker composition for diagnosing still's disease, diagnostic kit, and diagnostic method
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
MX2019010533A (es) Composicion para la medicion, prevencion o alivio del envejecimiento de la piel, usando hapln1.
SG11202006965QA (en) Liquid composition for oral use containing collagen peptide, and method for improving flavor of liquid composition for oral use including collagen peptide
MY186523A (en) Macrocyclic rip2 kinase inhibitors
KR102287153B9 (ko) 우유 엑소좀을 포함하는 피부 탄력 증진 및 주름 개선용 조성물
MX2025003917A (es) Mejoramientos en o relacionados con compuestos organicos
WO2017026691A9 (ko) 비만의 진단용 조성물 및 이의 용도
BR112019001130A2 (pt) uso de lactama e composição farmacêutica